BioGraph 55

San Francisco, CA · Founded 2014 · Privately Held (backing)

Developer of novel B-cell therapies and drugs designed to address significant unmet clinical needs of autoimmunity. BioGraph 55 is based in San Francisco, CA and was founded in 2014. Its last known valuation is $25 million. It has raised $20.1 million.

Last price · $/share
—
Implied valuation
$25.0M
Total raised
$20.1M
Last round
—
What is BioGraph 55 worth?
$25.0Mlast known valuation
Free account
More of BioGraph 55 with a free account
  • ·Watch BioGraph 55: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

BioGraph 55 funding history

No rounds on record

No funding rounds for BioGraph 55 are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

BioGraph 55 valuation

BioGraph 55's last known valuation is $25 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How BioGraph 55's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For BioGraph 55, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →

Frequently asked about BioGraph 55

What is BioGraph 55 worth?
BioGraph 55's last known valuation is $25.0M.
How much has BioGraph 55 raised?
BioGraph 55 has raised $20.1M in total funding across its recorded rounds.